{"id":"W2132037522","doi":"10.1016/j.lungcan.2004.11.029","title":"Sequential therapy with Vinorelbine followed by Gemcitabine in patients with metastatic non small cell lung cancer (NSCLC), performance status (PS) 2, or elderly with comorbidities—a multicenter phase II trial","year":2005,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal; Jewish General Hospital; Centre Hospitalier de l’Université de Montréal; Hôpital Charles-Le Moyne; McGill University; Royal Victoria Hospital","funders":"GlaxoSmithKline","keywords":"Vinorelbine; Gemcitabine; Medicine; Internal medicine; Lung cancer; Performance status; Population; Chemotherapy; Progressive disease; Oncology; Phases of clinical research; Antimetabolite; Gastroenterology; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001680824,0.00208059,0.003589035,0.0004902883,0.0004625039,0.001145593,0.001107577,0.001381001,0.004191377],"category_scores_gemma":[0.001169261,0.0007274734,0.001974702,0.0005755399,0.001057495,0.001351824,0.0005157861,0.004070503,0.0009490001],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001107838,"about_ca_system_score_gemma":0.001378777,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001735884,"about_ca_topic_score_gemma":0.004687409,"domain_scores_codex":[0.9995642,0.0001856874,0.00002264281,0.0001017167,0.00002811951,0.00009753407],"domain_scores_gemma":[0.9992003,0.0001432603,0.0001361739,0.00006733257,0.00003178046,0.0004211875],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9198987,0.01687204,0.002319599,0.000620666,0.001702616,0.00006294972,0.0001468746,0.002421307,0.005368733,0.0002227774,0.002420839,0.04794282],"study_design_scores_gemma":[0.8536946,0.1383765,0.004434105,0.0000391119,0.0004349478,0.00007082426,0.00004554744,0.001054695,0.0006599964,0.0002217256,0.0009429358,0.00002507151],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9928303,0.002864591,0.000353955,0.0005583764,0.0003545831,0.001056252,0.0006291808,0.00008163403,0.00127097],"genre_scores_gemma":[0.9873378,0.003418082,0.001542547,0.0009752743,0.0003040889,0.001582168,0.001722426,0.00003389335,0.00308361],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004191377,"threshold_uncertainty_score":0.01402152,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01192527405406834,"score_gpt":0.3126804444621362,"score_spread":0.3007551704080679,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}